{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:57:26Z","timestamp":1761901046729,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.msard.2013.11.001","type":"journal-article","created":{"date-parts":[[2013,11,28]],"date-time":"2013-11-28T15:45:18Z","timestamp":1385653518000},"page":"408-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod"],"prefix":"10.1016","volume":"3","author":[{"given":"Paul","family":"Schurmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhdeep","family":"Basra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar G.","family":"Awar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arya","family":"Basant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Dragan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yochai","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2013.11.001_bib1","unstructured":"Bonow RO, Mann DL, et al. Braunwald's Heart Disease. Ninth ed.; 2012. p. 798\u20139, p. 820\u20131."},{"key":"10.1016\/j.msard.2013.11.001_bib2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"for the TRANSFORMS study group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2013.11.001_bib3","unstructured":"EMA. European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya. \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2012\/04\/WC500125690.pdf\u3009 [accessed 20.04.12]."},{"key":"10.1016\/j.msard.2013.11.001_bib4","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1177\/1352458511410344","article-title":"Delayed fingolimod-associated asystole","volume":"17","author":"Espinosa","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2013.11.001_bib5","unstructured":"FDA, USA. FDA Drug Safety Communication: revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). \u3008http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm303192.htm\u3009 [accessed 14.05.12]."},{"key":"10.1016\/j.msard.2013.11.001_bib7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1096\/fj.03-0910fje","article-title":"The immunosuppressant FTY720 down regulates sphingosine 1-phosphate G-protein coupled receptors","volume":"18","author":"Graler","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.msard.2013.11.001_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"For the FREEDOMS study group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2013.11.001_bib9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1600-6143.2005.00754.x","article-title":"The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I","volume":"5","author":"Koyrakh","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.msard.2013.11.001_bib10","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1177\/1352458512438456","article-title":"Sudden unexpected death on fingolimod","volume":"18","author":"Lindsey","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2013.11.001_bib12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria","volume":"69","author":"Polman","year":"2010","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.msard.2013.11.001_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.NT.0000412581.41654.b2","article-title":"Health officials launch investigation in death of patients taking fingolimod","volume":"12","author":"Samson","year":"2012","journal-title":"Neurol Today"},{"key":"10.1016\/j.msard.2013.11.001_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00228-011-1146-9","article-title":"Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers","volume":"68","author":"Schmouder","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.msard.2013.11.001_bib15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1177\/0091270006289853","article-title":"FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects","volume":"46","author":"Schmouder","year":"2006","journal-title":"J Clin Pharmacol"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034813001260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034813001260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:36:19Z","timestamp":1761899779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034813001260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S2211034813001260"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2013.11.001","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2013.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}